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Abstract
We consider a model of fixed size N = 2l in which there are l generations of daughter cells
and a stem cell. In each generation i there are 2i−1 daughter cells. At each integral time
unit the cells split so that the stem cell splits into a stem cell and generation 1 daughter cell
and the generation i daughter cells become two cells of generation i+ 1. The last generation
is removed from the population. The stem cell gets first and second mutations at rates u1
and u2 and the daughter cells get first and second mutations at rates v1 and v2. We find the
distribution for the time it takes to get two mutations as N goes to infinity and the mutation
rates go to 0. We also find the distribution for the location of the mutations. Several outcomes
are possible depending on how fast the rates go to 0. The model considered has been proposed
by Komarova (2007) as a model for colon cancer.
Keywords: Cancer, Mutations, Poisson Process, Population Model
1 Introduction
In the 1950’s Armitage and Doll [1] proposed that cancer may be the end result of an accumulation
of two or more cell mutations. Komarova [5] discusses three mathematical models which may be
used to model the mutations that lead to cancer. The first is the Moran model, which may be
used to model cancers in liquids such as Leukemia. In this model there is a fixed population of
size N . There is a rate µ at which cells are getting mutations. Each cell in the population dies at
rate 1 and is replaced by any individual in the population, including itself, with equal probability.
The second is a spatial model which may be used to model cancers in solid tissues. This model
is similar to the Moran model except that the cells are given spatial locations and when they die
they are only replaced by nearby cells. The third model, the one we focus on in this paper, is
referred to as the hierarchical model in [5]. This model may be used for colon cancer.
As discussed in [5], many cells in the human body, including those in the colon, go through
a three step process. It begins with a stem cell which will stay in the population for a long time
and have many descendants. Some of these descendants will also be stem cells, but others will be
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differentiated progenitor cells. The progenitor cells, or what we shall refer to as daughter cells in
this paper, will split into more daughter cells. The number of times these cells split is dependent
upon what organ of the body they are in. We will refer to the number of splits that a daughter
cell has undergone as the generation of the cell. Once the cells split enough times they reach
maturity and are swept out of the population in a biological process called apoptosis.
The colon is lined with crypts that contain pockets of cells. The cells in the colon, as described
by Komarova in [7], are such that stem cells reside at the bottom of the crypt and the daughters
migrate up the crypt so that the higher generation daughter cells are near the top. We assume
that cancer is the result of two mutations, as is done in [5]. There are three ways in which the
mutations may occur. The stem cell may acquire both mutations so that cancer is a result of
mutations of the stem cell only. It is possible that stem cell receives the first mutation and a
daughter cell gets the second, or a daughter cell and one of its descendants will each receive
mutations before they are swept from the crypt. In [5] these cases are abbreviated as ss, sd and
dd respectively.
The Hierarchical model shall be referred to as H1. This model has a fixed population of size
N = 2l where l is the number of generations of daughter cells in the crypt. There is one stem
cell and for k ∈ {1, 2, . . . , l} there are 2k−1 daughter cells of generation k. We start with a full
crypt and no mutations. At each integral time unit all of the cells split in the following way:
• The stem cell splits into a stem cell and a generation 1 daughter cell.
• For each generation k with 1 ≤ k ≤ l− 1, a daughter cell of generation k will split into two
cells of generation k + 1.
• The daughter cells of generation l undergo apoptosis and are swept from the population.
Notice that the generations are constant size throughout time. The cells will accumulate muta-
tions via Poisson processes. A cell with 0, 1 or 2 mutations is called a type-0, type-1 or type-2
cell respectively. A mutation which occurs on a type-0 or type-1 cell is called a type-1 or type-2
mutation respectively. This terminology is used so that a mutation that makes a cell type-2 is
called a type-2 mutation. Once a type-2 mutation occurs the colon is assumed to have cancer.
The cells will each have two Poisson processes marking them, one which will cause type-1 muta-
tions and one which will cause type-2 mutations. The first Poisson process that marks a cell will
only cause a type-1 mutation if the cell is a type-0. If a mark of the Poisson process occurs while
the cell is not a type-0 then the mutation is rejected. Likewise, the second Poisson process only
causes mutations on type-1 cells. If a mark from this Poisson process occurs on a cell while it is
type-1 then the cell becomes type-2, but if the cell is not a type-1 then nothing happens. All of
the Poisson processes are independent. The mutations are passed to the descendants when a cell
splits. It is sometimes convenient to think of the cells as fixed in a binary tree and the mutations
as traveling through the tree in a direction which takes them from the root to the leaves. Because
of this we will often refer to the sequence of stem cells as the stem cell and we fix the Poisson
processes that are marking the cells on particular locations in the tree.
The rates at which the stem cell acquires type-1 and type-2 mutations are u1 and u2 respec-
tively. The rates at which the daughter cells get type-1 and type-2 mutations are v1 and v2
respectively. Each of the rates are functions of N and will approach 0 as N approaches infinity.
We will always consider what happens as N goes to infinity. All limits will be assumed as taking
N to infinity unless otherwise stated.
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We let τ(Ai) be the first time that any cell gets a type-2 mutation where Ai refers to a
model. We call a type-1 mutation to a cell which has a type-2 descendant successful. A type-1
mutation to a stem cell is always successful and a type-1 mutation to a daughter is successful
if the daughter has a type-2 descendent before its progeny is washed from the population. We
will call the successful type-1 mutation whose type-2 descendant is the first type-2 to occur the
cancer causing type-1 mutation. Being the cancer causing type-1 mutation is not equivalent to
being the first successful type-1 mutation. We also define random variables σ(Ai) and ρ(Ai) to
be the depth of the colon at which the cancer causing type-1 and first type-2 mutations occur,
respectively. More precisely, if the cancer causing type-1 mutation occurs in generation j then
we define σ(Ai) = j/l and if the first type-2 mutation occurs in generation k then we define
ρ(Ai) = k/l. If the cancer causing type-1 mutation or first type-2 mutation occur on the stem
cell then σ(Ai) = 0 or ρ(Ai) = 0 respectively.
The above establishes most of the notation that will be used throughout this paper, but some
more will be included here. For any real number a we define a+ = a∨ 0. For functions f(x) and
g(x) we will denote the limits f(x)/g(x)→ 0, f(x)/g(x)→ 1, and f(x)/g(x)→∞ as x→∞ by
f ≪ g, f ∼ g and f ≫ g respectively. We will also assume that there always exists a constant
α > 0 such that when ǫ > 0 we have
N−α−ǫ ≪ v2 ≪ N−α+ǫ. (1)
If α = 0 then the mutation rates are too fast to be realistic. To reduce the number of subscripts,
we will use log x for log2 x. We will use →d to denote convergence in distribution and →p to
denote convergence in probability.
One of the two goals of this paper is to find the asymptotic distribution of τ(H1) as N
approaches infinity. Similar work has been done for the Moran model by Schweinsberg in [9]
and Durrett, Schmidt and Schweinsberg in [3] in which more general results have already been
found. In [5], Komarova makes a connection between the Moran model and the hierarchical one as
follows: In the Moran model a mutation may undergo fixation, meaning it spreads throughout the
entire population through the birth-death process and all of the cells are the same type. Because
the last generation is always removed in the hierarchical model, the only way to get fixation is
if the stem cell gets mutated. These are the cases ss and sd. In these cases the mutation will
spread throughout the population in l time units. In the Moran model it is also possible that
the mutations undergo what is called stochastic tunneling. This is when multiple mutations are
acquired before they fixate. This is analogous to daughter cells acquiring two mutations before
the stem cell mutates in the hierarchical model. This is the dd case and can also happen in the
sd case if the second mutation occurs before the first has time to fixate (which is expected to
happen when α < 1). The rate at which daughter cells get successful type-1 mutations is given
heuristically in [5] to be
l∑
i=1
v12
i−1(1− e−v2(2l−i+1−2)).
One may arrive at this rate by noting that the ith generation has 2i−1 cells which get type-1
mutations at rate v1. Each of the cells will have 2
l−i+1 − 2 descendants which live for one time
each and get type-2 mutations at rate v2. The distribution of τ(H1) will be one part of the main
theorem.
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Our second goal is to determine which cells obtain the mutations that lead to cancer. The
location of the mutations can be essential to the treatment of cancer. As an example, studies of
the effects of the drug imatinib on chronic myeloid leukemia have shown that leukemic stem cells
will most likely not cause tumors but rather that a tumor is a result of a mutation on one of the
daughter cells, see Dingli and Michor [2] and Michor [8]. Imatinib treats leukemic daughter cells
but not leukemic stem cells. So while using imatinib problems arising from cancer are prevented.
However, patients cannot stop treatment because the leukemic stem cells will continue producing
new leukemic daughter cells. Therefore, the location of where the mutations occur may play a
pivotal role in determining how to treat the cancer. This is the other part of the main theorem
in which we determine the limiting distributions of σ(H1) and ρ(H1).
According to Komarova in [6] there are four cases that are particularly interesting from a
biological viewpoint.
1. The null-model. In this model all of the mutation rates are equal. This model is the easiest
to work with: u1 = u2 = v1 = v2.
2. Chromosomal instability. In this case the probability of getting a second mutation is greater
than that of getting the first mutation, but the rates do not differ between stem cells or
daughter cells: u1 = v1 < u2 = v2.
3. Stem cells have a lower mutation rate: v1 = v2 > u1 = u2.
4. The problem of de-differentiation. In this case the daughter cells have a slower mutation
rate. There are two scenarios for this: v1 = v2 < u1 = u2 or v1 = u1 = u2 > v2.
We impose the following restriction on the mutation rates: u1 ≤ u2 and v1 ≤ v2. This will cover
all of the above scenarios except for the second of the de-differentiation cases.
The following theorem is the goal of this paper. Recall that α is the number from (1).
Theorem 1. Recall that all limits are taken as N goes to infinity. Let X be a random variable
which has the exponential distribution with parameter 1 and let Y be a random variable which
has the Rayleigh distribution so that P (Y ≤ t) = 1− e−t2/2 for any t > 0.
1. If v1v2 ≪ 1/N(logN)2 and v1v2N logN ≫ u1 then (α ∧ 1)v1v2N(logN)τ(H1) →d X.
The distribution of σ(H1) converges to the uniform distribution on ((1−α)+, 1] and ρ(H1)
converges in probability to 1.
2. If 1/N(logN)2 ≪ v1v2 ≪ 1/N and
√
v1v2N ≫ u1 then
√
v1v2Nτ(H1) →d Y . Both σ(H1)
and ρ(H1) converge in probability to 1.
3. If v1v2 ≫ 1/N then
√
v1v2Nτ(H1) →d Y . Both σ(H1) and ρ(H1) converge in probability
to 1.
4. If we have the following two conditions:
• Either v1v2 ≪ 1/N(logN)2 and u1 ≫ v1v2N logN or 1/N(logN)2 ≪ v1v2 ≪ 1/N
and u1 ≫
√
v1v2N
• Both u2 ≪ 1/ logN and u2 ≪ Nv2
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then u1τ(H1) →d X. The probability that the first mutation occurs on the stem cell con-
verges to 1 and ρ(H1) converges in probability to α ∧ 1.
5. If we have the following two conditions:
• Either v1v2 ≪ 1/N(logN)2 and u1 ≫ v1v2N logN or 1/N(logN)2 ≪ v1v2 ≪ 1/N
and u1 ≫
√
v1v2N
• Either u2 ≫ 1/ logN or u2 ≫ Nv2
then u1 ≪ u2 implies u1τ(H1) →d X. On the other hand, if u1 ∼ Au2 for some A ≥ 1
then let Z be an exponentially distributed random variable with parameter 1/A which is
independent of X. Then u1τ(H1) →d X + Z. In either case, the probability that both
mutations occur on the stem cell converges to 1.
The first three cases in Theorem 1 are what happens when the probability that the cancer
causing type-1 mutation occurs on a daughter cell converges to 1. Case 4 gives the results for
the sd regime and case 5 gives the results for the ss regime.
The third case is a result of fast mutation rates. That is, there will be so many mutations
that the probability of two mutations occurring before the model even has time to split once will
converge to 1. This reduces to computing the waiting time for the first of N−1 Poisson processes
to receive two hits.
In both the first and second cases the probability that τ(H1) goes to infinity converges to
1. The results of these two cases rely on whether or not P (τ(H1) < logN) converges to 0 or 1.
As for the first case, P (τ(H1) < logN) → 0. The distribution of σ(H1) arises from a balance
between the large number of cells in the later generations versus the large number of descendants
of cells in the earlier generations.
For the second case P (τ(H1) < logN)→ 1. In this case the mutations occur fast enough that
the number of descendants the cells have is not as important. This is why the cancer causing
type-1 mutation will occur in the later generations.
In both the first and second cases the second mutation will occur near the top of the crypt.
This is because most of the cells are at the top of the crypt. The distribution of τ(H1) may be
best understood through the following picture:
An Alternative View of the Model
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 
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The horizontal axis is time and the vertical axis is cell generation. The circles represent
cell mutations. The circles within the rectangle represent successful type-1 mutations and the
other circles connected to these by a diagonal line which are located at the top of the graph
represent their type-2 descendants. The type-2 mutations are at the top of the graph because
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the later generations are where we expect the type-2 mutations to occur. Likewise, the type-1
mutations are expected to occur in the last αl generations so they lie above the line marked at
(1 − α)l. The infinite rectangle which is bounded between (1 − α)l and l vertically and only by
0 on the left horizontally will be dotted within by successful type-1 mutations according to a
Poisson process of rate v1v2N . This Poisson process has a uniform rate horizontally because of
the time independence of the mutation rates and uniform rate vertically because of the balance
between the number of cells in the later generations and the number of descendants of cells in
the earlier generations. Notice that in the picture the cancer causing type-1 mutation is not the
first successful type-1 mutation.
At times t1 and t2 there are diagonal lines coming out of the top of the graph that enclose
a region of the rectangle. To have a type-2 cell by time t1 we must have a successful type-1
mutation in the corresponding triangle. Likewise, to have a type-2 cell by time t2 we must have
a successful type-1 mutation in the corresponding quadrilateral. Therefore, the rate at which
type-2 mutations occur is converging to the area enclosed in the graph by time t multiplied by
the rate of successful type-1 mutations. For the first case we expect the time to get a second
mutation to be much larger than l which is represented by t2. Because of this, the waiting time
as marked on the graph will go infinitely to the right as N goes to infinity and the quadrilateral
will be approximately a rectangle since the missing bottom right corner will have negligible area.
This will cause τ(H1) to have an exponential distribution. For the second case we expect the
time to get a second mutation to be much smaller than l which is represented by t1. In this case
the area enclosed in the graph will always be a triangle so that the rate at which we expect to get
a type-2 mutation is asymptotic to a function of t2. This results in convergence to the Rayleigh
distribution. As N goes to infinity the triangle will be squeezed into the upper left corner.
The convergence of σ(H1) in part 1 is particularly interesting. The location of the cancer
causing type-1 mutation is not immediately obvious because the generations with large numbers
of cells have fewer descendants on which a type-2 mutations might occur. This result reveals
how the high rates of type-1 mutations occurring on later generations balances with the high
probability of success of type-1 mutations which occur on earlier generations.
In all but one case ρ(H1) converges to 1. This happens because of the large number of cells
in the later generations. The exception in case 4 is caused by having a low v1 and high u1 and
v2. The stem cell will get the first mutation because the daughter cells are slow to acquire type-1
mutations, but the daughter cells acquire type-2 mutations fast enough that they will get a type-2
mutation before all of the daughters inherit the type-1 mutation from the stem cell.
There are many boundary cases and most of them are not included in this paper, where we
use the term boundary case to refer to the boundary between two of the conditions. That is, if
v1 ≪ 1/N gives one result and v1 ≫ 1/N gives another, we would consider v1 ∼ A/N for some
constant A to be a boundary case. If included, the boundary cases would make up the bulk of
this paper. One reason for this is that our variables {v1, v2, u1, u2} span a four dimensional space
so that the regions will have many boundaries. Moreover, sometimes three regions intersect in
the same place. It does not seem that there would be any special difficulties in computing most
of these boundary cases and that they could be done with the same methods used in this paper.
The following proposition gives the results for the null-model, including results for the bound-
ary cases.
Proposition 2. Let µ = u1 = u2 = v1 = v2. Let X be a random variable which has the
exponential distribution with parameter 1. Let Y be a random variable which has the Rayleigh
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distribution.
1. If µ≪ 1/N logN then µτ(H1)→d X. The probability that the first mutation occurs on the
stem cell converges to 1 and ρ(H1) converges in probability to 1.
2. If µ ∼ A/N logN then (1 + A)µτ(H1) →d X. Let ξ be a Bernoulli random variable such
that P (ξ = 1) = A/(1 + A) and P (ξ = 0) = 1/(1 + A). Let U be a random variable with
uniform distribution on [0, 1]. Then
σ(H1)→d Uξ
and
ρ(H1)→d ξ + (α ∧ 1)(1 − ξ).
3. If 1/N logN ≪ µ ≪ 1/√N logN then (α ∧ 1)µ2N(logN)τ(H1) →d X. The distribu-
tion of σ(H1) converges to a uniform distribution on ((1 − α)+, 1] and ρ(H1) converges in
distribution to 1.
4. If µ ∼ A/√N logN then
limP (τ(H1)/ logN ≤ t) = (1− e−A2t2/2)1[0,1/2](t) + (1− e−A
2t/2+A2/8)1(1/2,∞)(t).
Let Z be a random variable with density
f(x) =
(∫ 1/2
1−x
A2e−A
2t2/2dt+ 2e−A
2/8
)
1[1/2,1](x).
As N goes to infinity σ(H1) converges in distribution to Z and ρ(H1) converges in probability
to 1.
5. If 1/
√
N logN ≪ µ ≪ 1/√N then √Nµτ(H1) →d Y . Both σ(H1) and ρ(H1) converge in
distribution to 1.
6. If µ ∼ A/√N then for each fixed time t > 0 there exist constants c and C such that
lim inf P (τ(H1) ≤ t) ≥ c > 0 and lim supP (τ(H1) ≤ t) ≤ C < 1. Both σ(H1) and ρ(H1)
converge in probability to 1.
7. If 1/
√
N ≪ µ then √Nµτ(H1)→d Y . Both σ(H1) and ρ(H1) converge in probability to 1.
Parts 1, 3, 5 and 7 of Proposition 2 follow directly from Theorem 1. Parts 2, 4 and 6, the
boundary cases, will be done in the last section. In part 2 the cancer causing type-1 mutation
may occur on the stem cell or a daughter cell. The event ξ = 1 indicates that the cancer causing
type-1 mutation occurred on a daughter cell. In part 4 the picture which appears below Theorem
1 is especially useful. We create a point process on [0,∞) × [0, 1] whose points are associated
with the mutations. In Lemma 23 we show that the limiting distribution of this point process
is a Poisson point process whose intensity is Lebesgue measure on [0,∞) × [1/2, 1]. The main
result of part 6 is that when µ ∼ A/√N the mutations will occur in finite time. Because of this,
the discreteness of the model cannot be ignored and computing the limit as N goes to infinity
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becomes difficult. However, this is a degenerate case because the model no longer resembles a
colon acquiring mutations.
In the next section we include some known results in probability that will be used throughout
the paper. In section 3 we introduce a new model which will be coupled with H1. Theorem 1 will
be proved with this new model in place of H1 and the coupling will give the results for H1. The
fourth section of this paper is devoted to getting results about the dd regime. The fifth section
is on results about the sd and ss regimes. In section 6 we determine whether τ(H1), σ(H1) and
ρ(H1) will satisfy the results of the dd, sd or ss regime. The proof of Theorem 1 is given at the
end of section 6. The last section is a discussion of the boundary cases in the null model and a
proof of Proposition 2.
2 Preliminaries
In this section we include some general results about probability which we will make use of in
the paper.
Lemma 3. If {Xn}∞n=1 is a sequence of nonnegative random variables such that Xn →d X for
some finite random variable X and {kn}∞n=1 is a sequence of positive constants such that kn → 0
then knXn →p 0.
Proof. Let ǫ > 0 and δ > 0 be real numbers. Let M be a real number such that the function
F (t) = P (X ≤ t) is continuous at Mǫ and P (X > Mǫ) < δ/2. Such an M exists because the
discontinuities of F are countable. Choose N1 so that if n ≥ N1 then kn < 1/M . Choose N2 so
that if n ≥ N2 then |P (Xn ≤Mǫ)− P (X ≤Mǫ)| < δ/2. Then for n ≥ N1 ∨N2
P (knXn > ǫ) ≤ P (Xn/M > ǫ)
≤ |P (Xn/M > ǫ)− P (X/M > ǫ)|+ P (X/M > ǫ)
≤ δ.
Lemma 4. Let {αn}∞n=1 and {βn}∞n=1 be sequences of positive numbers which converge to 0. Let
{Xn}∞n=1 and {Yn}∞n=1 be independent sequences of random variables and let X and Y be positive
random variables such that αnXn →d X and βnYn →d Y . If αn ≪ βn then P (Xn ≥ Yn)→ 1.
Proof. First note that P (Xn ≥ Yn) = P (αnXn ≥ αnYn). Also, αnYn = (αn/βn)βnYn and
αn/βn → 0 so αnYn →p 0 by Lemma 3.
Let δ > 0 and choose ǫ > 0 such that the function F (t) = P (X ≤ t) is continuous at ǫ and
P (X > ǫ) > 1− δ/2. We can choose N1 such that if n ≥ N1 then P (αnXn > ǫ) > 1 − δ by the
definition of convergence in distribution. Choose N2 such that if n ≥ N2 then P (αnYn > ǫ) < δ.
Then for n ≥ N1 ∨N2
P (αnXn > αnYn) ≥ P ({αnXn > ǫ} ∩ {ǫ > αnYn})
= P (αnXn > ǫ)P (ǫ > αnYn)
> (1− δ)2
where δ can be made arbitrarily small.
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Lemma 5. Let {An}∞n=0, {Bn}∞n=0 and {Cn}∞n=0 be sequences of events such that limn→∞ P (An) =
a > 0, limn→∞ P (Bn) = 1 and limn→∞ P (Cn) = 0. Then
lim
n→∞P (Bn|An) = 1 and limn→∞P (Cn|An) = 0.
Proof. First note that
lim
n→∞P (An ∩Cn) ≤ limn→∞P (Cn) = 0.
For n large enough P (An) is never 0, so limn→∞ P (Cn|An) = limn→∞ P (Cn ∩An)/P (An) = 0.
Likewise, limn→∞ P (BCn ) = 0 so limn→∞ P (BCn |An) = 0. Therefore, the same reasoning yields
limn→∞ P (Bn|An) = 1.
3 A Useful Model
There is a similar model H2 which will be coupled with model H1. This model is the same
as H1 except in the way the daughter cells acquire type-2 mutations. Label the daughter cells
D1,D2, . . . DN−1. In model H2 each daughter cell Di has a counter Ci starting at 0 and is acted
on by a sequence of Poisson processes {P in}∞n=1 which determine the type-2 mutations. All of the
Poisson processes are independent. In this model, when a type-1 mutation occurs on a daughter
cell Di it increases the counter Ci by 1. This is considered as a type-1 mutation. If a type-1
mutation increases the counter to n, it is the nth type-1 mutation on the cell. When the counter
Ci has reached n, any type-2 mutations that would occur according to the Poisson processes
P i1, P
i
2, . . . P
i
n are accepted as type-2 mutations on cell Di. Any type-2 mutations that would
occur according the the Poisson processes P in+1, P
i
n+2, . . . are rejected. If a type-2 mutation
occurs on cell Di as a result of the Poisson process P
i
n, then the n
th type-1 mutation according to
Ci is considered to be successful. If the first type-2 mutation on a cell is a result of the Poisson
process P in, then the n
th type-1 mutation according to Ci is the cancer causing type-1 mutation.
However, a type-1 mutation on the stem cell does not have a counter. Once a type-1 mutation
has spread from the stem cell to a daughter cell the daughter cell can no longer accumulate type-1
mutations and the model is the same as model H1.
There is an extra convenience embedded in the model H2. We can consider the N − 1
Poisson processes that mark the type-1 mutations on the individual daughter cells as one Poisson
process which marks the mutations on the population of daughter cells whose measure is time
independent. The rate of the Poisson process is v1(N − 1) and when a type-1 mutation occurs
it occurs on any particular cell with probability 1/(N − 1). In the Hierarchical model, H1, the
mutations are suppressed on type-1 cells so that the rate at which the population of daughter
cells is acquiring type-1 mutations depends on how many type-1 cells there are at the time.
We couple H1 and H2 by allowing the same Poisson processes to mark the mutations on
the cells within each model. The Poisson processes that mark the stem cells are the same. If
a daughter cell has inherited a type-1 mutation from the stem cell then the Poisson processes
marking type-2 mutations on the cell are the same in each model. The Poisson processes marking
type-1 mutations on daughter cells are the same. The Poisson processes marking type-2 mutations
on daughter cells in model H1 are the same as the Poisson processes P
i
1 in model H2 so long
as the daughter cells did not inherit their type-1 mutations from the stem cell. There are no
analogous Poisson processes in model H1 for the N − 1 sequences of Poisson processes P i2, P i3, . . .
in model H2.
9
Lemma 6. Let the Poisson processes in models H1 and H2 be coupled as described above. Then
P (τ(H1) = τ(H2)), P (ρ(H1) = ρ(H2)) and P (σ(H1) = σ(H2)) all converge to 1.
Proof. A type-2 mutation which occurs in model H2 but not in H1 is a result of the rejection
of the type-1 mutation in model H1 that has led to the type-2 mutation in H2. This mutation
is rejected because the cell on which the type-1 mutation was supposed to occur already was a
type-1 cell. Any cell has at most logN ancestors, so the probability that a type-1 mutation is
rejected is less than e−v1 logN . Therefore, the probability of rejecting the type-1 mutation that
causes the first type-2 mutation is converging to 0 as long as v1 ≪ 1/ logN . That is, if we number
the cells 1, 2, . . . , N and let Ai be the event that the cancer causing mutation happens on cell i,
P (τ(H1) 6= τ(H2)) =
N∑
i=1
P (τ(H1) 6= τ(H2)|Ai)P (Ai) ≤
N∑
i=1
e−v1 logNP (Ai) = e−v1 logN → 0.
If we do not have v1 ≪ 1/ logN then because v2 ≥ v1 we do not have v2 ≪ 1/ logN either,
with contradicts equation (1). Hence we only need to consider the case v1 ≪ 1/ logN .
The rest of the work in proving Theorem 1 is in proving Theorem 1 with H2 in place of H1.
Once this is done Theorem 1 follows from Lemma 6.
4 The dd regime
To understand the behavior in the dd regime, we consider a new model which is the same as H2
except that mutations only occur on daughter cells. That is, there are no Poisson processes that
cause mutations on the stem cells. This new model will be called model M1. The purpose of this
section is to prove Proposition 7.
Proposition 7. Let X be a random variable which has the exponential distribution with parameter
1. Let Y be a random variable which has the Rayleigh distribution.
1. If v1v2 ≪ 1/N(logN)2 then (α ∧ 1)v1v2N(logN)τ(M1) →d X. The distribution of σ(M1)
converges to a uniform distribution on ((1 − α)+, 1] and ρ(M1) converges in probability to
1.
2. If 1/N(logN)2 ≪ v1v2 ≪ 1/N then
√
Nv1v2τ(M1)→d Y . Both σ(M1) and ρ(M1) converge
in probability to 1.
3. If v1v2 ≫ 1/N then
√
Nv1v2τ(M1) →d Y . Both σ(M1) and ρ(M1) converge in probability
to 1.
Lemma 8. For any positive integer k < l we have P (ρ(M1) ≥ (l − k)/l) > 1− 1/2k.
Proof. Let Y be the number of generations between the cancer causing type-1 mutation and the
first type-2 mutation. Then Y ∈ {1, 2, . . . , l}. Because there are only l generations, if the second
mutation occurs l−k generations or more after the first then it must be in the last k generations.
So P (ρ(M1) ≥ (l−k)/l|Y ∈ {l−k, l−k+1, . . . , l}) = 1. If we condition on the event that Y = k,
then the probability that the cancer causing type-1 mutation occurs on any cell in generations
1, 2, . . . , l − Y is equally likely. This is because the descendants of the cells are independent and
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identically distributed. The last k of the l− Y generations always make up at least a fraction of
1− 1/2k cells, so we have P (ρ(M1) ≥ (l− k)/l|Y ∈ {1, 2, . . . , l− k− 1}) > 1− 1/2k where we get
a strict inequality because we do not count the stem cell. The result follows.
It is important to notice in the above lemma that we do not need N →∞. We can see from
the above lemma that P (ρ(M1) ≥ (l − k)/l) > 1 − 1/2k holds for any N so it remains valid as
N →∞.
Corollary 9. As N goes to infinity, ρ(M1) will converge to 1 in probability.
Lemma 10. Let (β1, β2] ⊂ (0, 1] and let C and C ′ be a positive constants. Then∑
i∈N∩(lβ1,lβ2]
v12
i−1(1− e−Cv2(2l−i+1−C′)) ∼ C(β2 − β1 ∨ (1− α))+v1v2N logN.
Proof. We will first define some notation for this proof for the sake of readability. Let I ⊂ R.
We define
I∗ := I ∩ (lβ1, lβ2] ∩ N.
First we can do the case when α ≥ 1. Let 0 < ǫ < 1 and break the sum into two parts,
∑
i∈(lβ1,lβ2]∗ v12
i−1(1− e−Cv2(2l−i+1−C′))
v1v22ll
=
(
∑
i∈[1,lǫ]∗ +
∑
i∈(lǫ,l]∗)2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
.
If we use the upper bound 1− e−Cv2(2l−i+1−C′) ≤ Cv2(2l−i+1 − C ′) ≤ Cv22l−i+1 then
0 ≤
∑
i∈[1,lǫ]∗ 2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
≤ C(β2 ∧ ǫ− β1)+.
As for the second sum, the same upper bound yields
∑
i∈(lǫ,l]∗ 2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
≤ C(β2 − β1 ∨ ǫ)+.
From the second order Taylor expansion we get a lower bound of
1− e−C(2l−i+1−C′) ≥ Cv2(2l−i+1 − C ′)− 1
2
C2v22(2
l−i+1 − C ′)2.
We can show that this sum will go up to 1− ǫ by breaking the sum into 5 parts,
2i−1(1− e−Cv2(2l−i+1−C′)) ≥ 2lCv2 − 2iCC ′v2 − 22l−iC2v22 + 2lC2C ′v22 − 2i−2C2(C ′)2v22 .
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We get the following computations for each of the five individual sums:∑
i∈(lǫ,l]∗
2lCv2/v22
ll→ C(β2 − β1 ∨ ǫ)+.
∑
i∈(lǫ,l]∗
2iCC ′v2/v22ll ≤ CC ′2l+1/(2ll)→ 0.
∑
i∈(lǫ,l]∗
2i−2C2(C ′)2v22/v22
ll ≤ 2C2C ′2v2/l → 0.
∑
i∈(lǫ,l]∗
2lC2C ′v22/v22
ll ≤ C2C ′v2 → 0.
∑
i∈(lǫ,l]∗
22l−iC2v22/v22
ll = C2v22
l(
l∑
i=⌈lǫ⌉
2−i)/l ≤ C2v22l(1−ǫ) → 0
so long as v2 ≪ 1/2l(1−ǫ) = N−1+ǫ which will hold since this is the case α ≥ 1.
So we have
C(β2 − β1 ∨ ǫ)+ ≤ lim inf
∑
i∈(lβ1,lβ2]∗ v12
i−1(1− e−Cv2(2l−i+1−C′))
v1v22ll
and because (β2 − β1 ∨ ǫ)+ + (β2 ∧ ǫ− β1)+ = β2 − β1 we also have
lim sup
∑
i∈(lβ1,lβ2]∗ v12
i−1(1− e−Cv2(2l−i+1−C′))
v1v22ll
≤ C(β2 − β1).
Since ǫ may be made arbitrarily small we have finished the case for α ≥ 1.
Now let 0 < α < 1 and let ǫ > 0 be small enough so that 0 < 1− α− ǫ < 1− α+ ǫ < 1. We
now break the sum into three pieces,
(
∑
i∈[1,l(1−α−ǫ))∗ +
∑
i∈[l(1−α−ǫ),l(1−α+ǫ)]∗ +
∑
i∈(l(1−α+ǫ),l]∗)2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
.
We can consider each of these three sums individually.
As for the middle sum, we only need the bound
0 ≤
∑
i∈[l(1−α−ǫ),l(1−α+ǫ)]∗ 2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
≤ 2Cǫ
which follows by the upper bound 1− e−Cv2(2l−i+1−C′) ≤ Cv22l−i+1.
One can apply similar computations as in the case when α = 1 to obtain the following:
∑
i∈(l(1−α+ǫ),l]∗ 2
i−1(1− e−Cv2(2l−i+1−C′))
v22ll
→ C(β2 − β1 ∨ (1− α+ ǫ))+.
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For the first sum, note that 1− e−Cv2(2l−i+1−C′) ≤ 1. This gives the bound
0 ≤
∑
i∈[1,l(1−α−ǫ))∗
2i−1(1− e−Cv2(2l−i+1−C′))
v22ll
≤
∑
i∈[1,l(1−α−ǫ))∗
2i−1
v22ll
≤ 2
l(1−α−ǫ)
v22ll
→ 0.
The convergence is a result of the definition of α, namely that v2 ≫ N−α−ǫ log−1N .
Combining the three sums yields
C(β2 − β1 ∨ (1− α+ ǫ))+ ≤ lim inf
∑
i∈(lβ1,lβ2]∗ v12
i−1(1− e−Cv2(2l−i+1−C′))
lv1v22l
and
lim sup
∑
i∈(lβ1,lβ2]∗ v12
i−1(1− e−Cv2(2l−i+1−C′))
lv1v22l
≤ C(β2 − β1 ∨ (1− α+ ǫ))+ + 2Cǫ.
Again, ǫ may be arbitrarily small which gives the result.
Corollary 11. For any time t, the rate at which successful type-1 mutations occur is asymptotic
to (α ∧ 1)v1v2N logN .
Proof. For 1 ≤ i ≤ l there are 2i−1 cells in generation i. Each of these cells is getting type-1
mutations at rate v1. The cells in generation i have 2
l−i+1 − 2 descendants. If the cell splits as
soon as it becomes a type-1, the probability that none of its descendants get a type-2 mutation
is e−v2(2l−i+1−2). On the other hand, after a cell gets a type-1 mutation it could live for at most 1
time unit until it splits. If this is the case, then the probability that neither the cell that receives
the type-1 mutation nor any of its descendants get a type-2 mutation is e−v2(2
l−i+1−1). If we let
R(t) be the rate at which the successful type-1 mutations occur at time t, then for any time t we
have
1 = lim
∑l
i=1 v12
i−1(1− e−v2(2l−i+1−2))
(α ∧ 1)v1v2N logN ≤ lim inf
R(t)
(α ∧ 1)v1v2N logN
≤ lim sup R(t)
(α ∧ 1)v1v2N logN ≤ lim
∑l
i=1 v12
i−1(1− e−v2(2l−i+1−1))
(α ∧ 1)v1v2N logN = 1,
where the limits are results of Lemma 10.
Lemma 12. If v1v2 ≪ 1/N(logN)2 then the distribution of σ(M1) converges to the uniform
distribution on ((1− α)+, 1].
Proof. Let X1 be the time at which the cancer causing mutation occurs and let Y1 be the time at
which the first successful type-1 mutation occurs. By Corollary 11 we have that the random vari-
able (α ∧ 1)v1v2N(logN)Y1 is converging in distribution to an exponentially distributed random
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variable with parameter 1. Let Y2 be the time it takes to get the second successful type-1 mutation
after the first and let X2 = τ(M2)−Y1. As a result of Corollary 11 again, (α∧ 1)v1v2N(logN)Y2
converges in distribution to an exponentially distributed random variable with parameter 1. Then
because a type-2 mutation must occur within logN time after a successful type-1 mutation on a
daughter cell we have
P (Y2 < X2) ≤ P (Y2 < logN) = P ((α ∧ 1)v1v2N(logN)Y2 < (α ∧ 1)v1v2N(logN)2)→ 0.
Moreover, P (Y2 ≥ X2) ≤ P (Y1 = X1) so P (Y1 = X1) → 1. Therefore, it is enough to find the
distribution of the first successful type-1 mutation.
Each generation i with 1 ≤ i ≤ l is getting successful type-1 mutations independently at a
rate bounded between v12
i−1(1 − e−v2(2l−i+1−2)) and v12i−1(1 − e−v2(2l−i+1−1)) for any time t.
Therefore, for a fixed N and i, the probability that the first successful type-1 mutation occurs
on generation i is between
v12
i−1(1− e−v2(2l−i+1−2))∑l
j=1 v12
j−1(1− e−v2(2l−j+1−1))
and
v12
i−1(1− e−v2(2l−i+1−1))∑l
j=1 v12
j−1(1− e−v2(2l−j+1−2)) .
Let β ∈ [0, 1]. Using the notation and result from Lemma 10,
lim supP (σ(M1) ≤ β) ≤ lim sup
∑
i∈(0,lβ]∗ v12
i−1(1− e−v2(2l−i+1−1))∑
i∈(0,l]∗ v12j−1(1− e−v2(2l−j+1−2))
=
(β − (1− α)+)+
α ∧ 1
and
lim inf P (σ(M1) ≤ β) ≥ lim inf
∑
i∈(0,lβ]∗ v12
i−1(1− e−v2(2l−i+1−2))∑
i∈(0,l]∗ v12j−1(1− e−v2(2l−j+1−1))
=
(β − (1− α)+)+
α ∧ 1 .
Lemma 13. If v1v2 ≪ 1/N(logN)2 then (α ∧ 1)v1v2N(logN)τ(M1) →d X where X is an
exponential random variable with parameter 1.
Proof. Let X1 be the time at which the cancer causing type-1 mutation occurs and let X2 =
τ(M1)−X1. From the proof of Lemma 12 we know that the probability that the first successful
type-1 mutation is the cancer causing mutation is converging to 1. By Corollary 11 we know
that the rate of successful type-1 mutations is approaching (α ∧ 1)v1v2N logN . This gives us
that (α∧1)v1v2N(logN)X1 is converging in distribution to an exponentially distributed random
variable with parameter 1.
Let ǫ > 0. Due to apoptosis X2 is bounded above by logN so
P ((α ∧ 1)v1v2N(logN)X2 > ǫ)→ 0.
In other words, (α ∧ 1)v1v2N(logN)X2 →p 0. Then
(α ∧ 1)v1v2N(logN)τ(M1) = (α ∧ 1)v1v2N(logN)(X1 +X2)→d X.
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Combining the results of Corollary 9 and Propositions 12 and 13 we have part 1 of Proposition
7. For the next two proofs we note that Corollary 9 already gives us that ρ(M1) converges to 1
in probability.
Proof of part 2 of Proposition 7. Consider generation i for some i ∈ {1, . . . , l} at time 0. The
total number of descendants of the cells in generation i is 2l−i+1 − 2. However, if t < l − i then
the total number of descendants by time t is between 2t−1 and 2t+1. At each integral time unit
there is a new collection of cells in generation i. We can consider a sequence of collections of
cells where the first element in the sequence is the collection of cells in generation i during time
[0, 1), the second element is the collection of cells in generation i during time [1,2), and so on.
Because the Poisson processes marking the type-1 mutations in model H2 are independent of
the type-1 mutations that have already occurred we can consider the sequence of cells in these
generations and their descendants that occur over time to be independent. Also, the random
variables denoting the times at which type-2 mutations occur as a result of type-1 mutations on
the cells in generation i would be identically distributed if we were to start each new collection
of cells in generation i at time 0. If t < l − i then by time t the number of cells which will have
descended from the jth element in the sequence will be between 2t−1−j and 2t+1−j for j ≤ ⌊t⌋.
If we sum over all of the terms in the sequence which have appeared by time t, the total number
of cells which have descended from a cell in generation i (including those which have already
undergone apoptosis) will be between
⌊t⌋∑
j=0
2t−1−j ≥ 2t − 1
and
⌊t⌋∑
j=0
2t+1−j ≤ 2t+2 − 1.
If t ≥ l − i then by time t the total number of cells which will have descended from a cell in
generation i will be between
l−i∑
j=0
2l−i−j−1 + (t− l + i)(2l−i+1 − 2) = 2l−i − 1 + (t− l + i)(2l−i+1 − 2)
and
l−i∑
j=0
2l−i−j+1 + (t− l + i)(2l−i+1 − 2) = 2l−i+2 − 1 + (t− l + i)(2l−i+1 − 2).
Recall that there are always 2i−1 cells in generation i which are acquiring type-1 mutations at
rate v1. If we multiply the rate of type-1 mutations on generation i by the probability that such a
mutation is successful, we find that the type-2 mutations that occur as a result of successful type-
1 mutations that occur on generation i occur according to a Poisson process that has intensity
measure between
2i−1v1(1− e−v2(2t−1)) and 2i−1v1(1− e−v2(2t+2−1))
if t < l − i and
2i−1v1(1− e−v2(2l−i−1+(t−l+i)(2l−i+1−2))) and 2i−1v1(1− e−v2(2l−i+2−1+(t−l+i)(2l−i+1−2)))
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if t ≥ l − i.
First we concentrate on the upper bound. For N large enough we will have t <
√
v1v2N logN
for any real number t by the hypothesis 1/N(logN)2 ≪ v1v2. Let t/
√
v1v2N < l. Then
P (τ(M2) ≤ t√
v1v2N
) = 1− e−f(N,t)
where by summing over the generations and using the fact that 1− e−x ≤ x we obtain
f(N, t) ≤
∑
0≤i<l− t√
v1v2N
2i−1v1(1− e−v2(2
t/
√
v1v2N+2−1))
+
∑
l− t
v1v2N
≤i≤l
2i−1v1(1− e−v2(2l−i+2−1+(t/
√
v1v2N−l+i)(2l−i+1−2)))
≤
∑
0≤i<l− t√
v1v2N
2i−1(2t/
√
v1v2N+2 − 1)v1v2
+
∑
l− t
v1v2N
≤i≤l
2i−1
(
2l−i+2 − 1 +
(
t√
v1v2N
− l + i
)
(2l−i+1 − 2)
)
v1v2.
As for the first sum,
∑
0≤i<l− t√
v1v2N
2i−1(2t/
√
v1v2N+2 − 1)v1v2 ≤ 1
2
(2t/
√
v1v2N+2 − 1)(2l−t/
√
v1v2N+1 − 1)v1v2
≤ 2l+2v1v2 → 0.
As for the second sum, we first compute
∑
l− t√
v1v2N
≤i≤l
2i−1(2l−i+2 − 1)v1v2 ≤ 2l+2v1v2 t√
v1v2N
→ 0.
Lastly,
∑
l− t√
v1v2N
≤i≤l
2i−1
(
t√
v1v2N
− l + i
)
(2l−i+1 − 2)v1v2 ≤ 2lv1v2
∑
l− t√
v1v2N
≤i≤l
(
t√
v1v2N
− l + i
)
≤ 2
lv1v2
2
(
t√
v1v2N
+ 1
)2
→ t
2
2
.
Therefore, lim supP (
√
v1v2Nτ(M2) ≤ t) ≤ 1− e−t2/2.
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As for the lower bound, we have
f(N, t) ≥
∑
0≤i<l− t√
v1v2N
2i−1v1(1− e−v2(2
t/
√
v1v2N−1))
+
∑
l− t√
v1v2N
≤i≤l
2i−1v1(1− e−v2(2l−i−1+(t/
√
v1v2N−l+i)(2l−i+1−2)))
≥
∑
l− t√
v1v2N
≤i≤l
2i−1v1(1− e−v2(t/
√
v1v2N−l+i)(2l−i+1−2)).
Using the bound 1− e−x ≥ x− x2/2 we have∑
l−t/√v1v2N≤i≤l
2i−1v1(1− e−v2(t/
√
v1v2N−l+i)(2l−i+1−2))
will be greater than or equal to the sum over i ∈ [l − t/√v1v2N, l] of
2i−1v1
(
v2
(
t√
v1v2N
− l + i
)
(2l−i+1 − 2)− v22
(
t√
v1v2N
− l + i
)2
(2l−i+1 − 2)2/2
)
.
First consider ∑
l−t/√v1v2N≤i≤l
2i−1v1v22
(
t√
v1v2N
− l + i
)2 (2l−i+1 − 2)2
2
.
This sum is bounded between 0 and
∑
l−t/√v1v2N≤i≤l v2t
22l−i. Let 0 < ǫ < α. For N large enough
we have t <
√
v1v2Nl(α − ǫ) which is equivalent to l(1− α− ǫ) < l − t/
√
v1v2N. So for N large
enough we have ∑
l−t/√v1v2N≤i≤l
v2t
22l−i ≤
∑
l−l(1−α+ǫ)≤i≤l
v2t
22l−i ≤ lv2Nα−ǫ → 0.
This leaves us to show
lim inf
∑
l−t/√v1v2N≤i≤l
2i−1v1v2
(
t√
v1v2N
− l + i
)
(2l−i+1 − 2) ≥ t
2
2
.
Let j ∈ N and t > 0. By our assumptions, for large enough values of N we will have j <
t/
√
v1v2N < logN . Notice that if i ≤ l − j then 2l−i+1 − 2 ≥ (1− 2−j)2l−i+1, so
∑
l−t/√v1v2N≤i≤l
2i−1v1v2
(
t√
v1v2N
− l + i
)
(2l−i+1 − 2)
≥
∑
l−t/√v1v2N≤i≤l−j
2i−1v1v2
(
t√
v1v2N
− l + i
)
(1− 2−j)2l−i+1.
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Because j is fixed we have
∑
l−j≤i≤l
2i−1v1v2
(
t√
v1v2N
− l + i
)
(1− 2−j)2l−i+1 → 0
since each of the summands converges to 0. Therefore, we can add this sum without changing
the limit. This gets us a lower bound of
lim inf
∑
l−t/√v1v2N≤i≤l
2lv1v2
(
t√
v1v2N
− l + i
)
(1− 2−j) ≥ t
2
2
(1− 2−j).
We chose j to be any natural number, so lim inf P (
√
v1v2Nτ(M2) ≤ t) ≥ 1− e−t2/2.
The above two bounds establish that P (
√
v1v2Nτ(M2) ≤ t)→ 1− e−t2/2 for any t ≥ 0. This
leaves us to show that σ(M1) converges in probability to 1. First note that for any ǫ > 0 we have
P (τ(M1) ≤ ǫ logN) = P (
√
Nv1v2τ(M1) ≤
√
Nv1v2ǫ logN)→ 1
which follows because the distribution of
√
Nv1v2τ(M1) is converging to the Rayleigh distribution
and
√
Nv1v2ǫ logN is converging to 0. Let δ > 0. By Corollary 9 we know that ρ(M1) converges
in probability to 1 so that as N goes to infinity, P (ρ(M1) > 1 − δ) → 1. If σ(M1) < 1 − 2δ
and ρ(M1) > 1 − δ then τ(M1) > δ logN . Because P (τ(M1) > δ logN) → 0 we must also have
P (σ(M1) < 1− 2δ)→ 0 where δ > 0 was arbitrary. Then P (1− σ(M1) > 2δ)→ 0 for any δ > 0
so σ(M1)→p 1.
Proof of part 3 of Proposition 7. We shall make use of the following well known fact: If {an}∞n=1
is a sequence of real numbers such that an → a, then
lim
n→∞(1−
an
n
)n−1 = ea.
Before time 1 the cells never split and there is no apoptosis. If we ignore the splitting and
apoptosis and consider how long it takes for a cell to acquire two mutations under the mutation
mechanism alone then we have N−1 cells acquiring mutations independently. For any individual
cell, the time it takes to acquire two mutations will have the same distribution as the sum of two
independent exponentially distributed random variables with parameters v1 and v2. If we denote
the time until cell i has a type-2 mutation by Ti and assume v1 6= v2 then
P (Ti ≤ t) = 1− v2e
−v1t − v1e−v2t
v2 − v1 .
There are N − 1 cells independently getting mutations, so for t ≤ 1 we have
P (τ(M1) ≤ t) = 1−
(
v2e
−v1t − v1e−v2t
v2 − v1
)N−1
,
or equivalently,
P (
√
v1v2Nτ(M1) ≤ t) = 1−
(
v2e
−
√
v1/v2Nt − v1e−
√
v2/v1Nt
v2 − v1
)N−1
.
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By using the third degree Taylor expansion of the exponential function we get the bounds
1− t
2
2N
−
√
v31
v2N3
t3
6
≤ v2e
−
√
v1/v2Nt − v1e−
√
v2/v1Nt
v2 − v1 ≤ 1−
t2
2N
+
√
v32
v1N3
t3
6
.
Notice that N
√
v31/v2N
3 = v21/
√
v1v2N → 0 and N
√
v32/v1N
3 = v22/
√
v1v2N → 0. Then for
any fixed t we have 
1− t2
2N
−
√
v31
v2N3
t3
6


N−1
→ t
2
2
and 
1− t2
2N
+
√
v32
v1N3
t3
6


N−1
→ t
2
2
.
If v1 = v2 then the probability that one cell has two mutations by time t is 1 − e−v1t −
v1te
−v1t if we ignore splitting and apoptosis. The probability that one of the N cells has two
mutations by time t is 1− (e−v1t− v1te−v1t)N . By applying the same techniques as above we get
P (
√
v1v2Nτ(M1) ≤ t)→ 1− e−t2/2 when v1 = v2.
Combining the two results above we have P (
√
v1v2Nτ(M1) ≤ t)→ 1− e−t2/2 when ignoring
splitting and apoptosis. Then P (τ(M1) < 1) = P (
√
v1v2Nτ(M1) <
√
v1v2N) → 1. Therefore,
the probability that two mutations occur before time 1 is converging to 1 so we may ignore
splitting and apoptosis in this case. This gives the desired result for τ(M1).
By Corollary 9 we know that ρ(M1) converges in probability to 1. Because the two mutations
occur before splitting or apoptosis, the probability that the cancer causing type-1 mutation and
the first type-2 mutation are on the same cell converges to 1. Therefore, σ(H1) converges to 1 in
probability.
5 The sd and ss regimes
In this section we need two different models. The first one is the same as model H2 except that
only the stem cell receives type-1 mutations and only the daughter cells receive type-2 mutations.
The second is the same as H2 except that only the stem cell receives mutations. These will be
referred to as models M2 and M3 respectively.
Proposition 14. Let X be a random variable which has an exponential distribution with param-
eter 1.
1. If u1 ≪ 1/ logN and u1 ≪ Nv2 then u1τ(M2)→d X and ρ(M2) converges in probability to
α ∧ 1.
2. If u1 ≪ u2 then u1τ(M3)→d X.
3. Let A ≥ 1 and Z be an exponentially distributed random variable with parameter 1/A which
is independent of X. If u1 ∼ Au2 then u1τ(M3)→d X + Z.
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The goal of this section is to prove Lemma 14. It will be shown later that the conditions used
in Lemma 14 for the sd regime are the only relevant conditions.
Define X1 to be the time at which the cancer causing type-1 mutation occurs and define X2
to be the time after the cancer causing type-1 mutation until the first type-2 mutation. Note
that because the stem cell is the only cell that gets type-1 mutations in models M2 and M3 that
the first successful type-1 mutation is also the cancer causing type-1 mutation.
Lemma 15. Consider the model M2. For time t ≤ logN after the stem cell receives a type-1
mutation we have
P (X2 > t) ≥ e−2t+2v2 and P (X2 > t) ≤ e−(2t−2−2)v2 .
Proof. First we establish the upper bound. After the stem cell gets the first mutation it takes
at most one time unit until the mutation is passed along to the first generation daughter cell.
Assuming it does take one time unit until the first generation daughter cell inherits the mutation
we can get an upper bound on P (X2 > t). Let time t = 0 denote the time at which the stem cell
receives the type-1 mutation. There are no mutations being acquired by the daughter cells for time
t ∈ [0, 1). For time t ∈ [1, 2) the generation 1 daughter cell is the only type-1 daughter cell. So
for t ∈ [1, 2) we have P (X2 > t) = e−(t−1)v2 . For time t ∈ [2, 3) the first two generations have the
mutation which is a total of 3 cells. Therefore, for t ∈ [2, 3) we have P (X2 > t) = e−(3(t−2)v2+v2)
where the v2 is added because of the probability of having a mutation before time 2. Extending
this inductively gives us
P (X2 > t) ≤ e−[(2⌊t⌋−1)(t−⌊t⌋)+
∑⌊t⌋
i=2(2
i−1−1)]v2 ≤ e(−2t−2−1)v2
for any t ≤ logN .
For the lower bound we use the same reasoning as above except that we assume it takes 0
time for the generation 1 daughter cell to become a type-1 after the stem cell is a type-1. This
gets us
P (X2 > t) ≥ e−[(2⌈t⌉−1)(t−⌊t⌋)+
∑⌊t⌋
i=1(2
i−1)]v2 ≥ e−2t+2v2 .
Lemma 16. The location of the second mutation satisfies ρ(M2)→p α ∧ 1.
Proof. By Lemma 15 we have P (X2 > logN) ≥ e−4Nv2 . If α > 1 then P (X2 > logN) converges
to 1 and the mutation will spread throughout the entire crypt. If this is the case then any cell is
equally likely to have the second mutation. Therefore P (ρ(M2) ≤ β) ≤ (2βl − 1)/(2l − 1) for any
β ∈ [0, 1) so ρ(M2)→p 1.
Now suppose α ≤ 1. Let ǫ > 0 so that α− ǫ > 0. Then by Lemma 15
P (X2 > l(α− ǫ)) ≥ e−2l(α−ǫ)+2v2 .
Because 4Nα−ǫv2 → 0 we get the convergence P (X2 > l(α − ǫ)) → 1. By time l(α − ǫ) the
mutation will have spread to the first ⌊l(α − ǫ)⌋ generations so that for times after l(α − ǫ) we
know that at least 2⌊l(α−ǫ)⌋ cells have the type-1 mutation. Therefore,
P ({ρ(M2) ≤ β} ∩ {X2 > l(α− ǫ)}) ≤ (2βl − 1)/(2(α−ǫ)l−1 − 1).
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Thus, for any β < α− ǫ,
P (ρ(M2) ≤ β) < 2
βl − 1
2(α−ǫ)l−1 − 1 + P (X2 ≤ l(α− ǫ))→ 0
Hence P (ρ(M2) ≥ α− ǫ)→ 1. Because ǫ may be arbitrarily small we have finished the case when
α = 1.
Suppose α < 1 and let ǫ > 0 so that α+ ǫ ≤ 1. Then by Lemma 15
P (X2 > l(α+ ǫ)) ≤ e−(2l(α+ǫ)−2−1)v2 .
Because Nα+ǫv2/4→∞, we have P (X2 > l(α+ ǫ))→ 0. By time l(α+ ǫ) the mutation has only
spread to the first l(α+ ǫ) generations, so P (ρ(M2) > α+ ǫ)→ 0 where ǫ is arbitrarily small.
Lemma 17. If u1 ≪ 1/ logN and u1 ≪ Nv2 then u1τ(M2) →d X where X has exponential
distribution with parameter 1.
Proof. Since the stem cell is getting mutations according to a Poisson process at rate u1 we have
that u1X1 is an exponentially distributed random variable with parameter 1. This leaves us to
show u1X2 →p 0.
Suppose we consider a new model M ′2 which is the same as model M2 except that the type-2
mutations can only occur on daughter cells logN time after the stem cell has a type-1 mutation.
We can couple models M2 andM
′
2 so that the same Poisson processes are marking the mutations
on the daughter cells in each model but that any proposed type-2 mutation is rejected in model
M ′2 until logN time after the stem cell mutation. This way X1 is the same in modelsM2 andM
′
2.
Also, if we let X ′2 = τ(M
′
2)−X1 then X ′2 ≥ X2. Therefore it is enough to show that u1X ′2 →p 0.
If we wait logN time after the stem cell receives its type-2 mutation then all of the daughter
cells will be type-1. Then the (N − 1) daughter cells are getting type-2 mutations at rate v2.
Thus for any fixed N we have
P (X ′2 > t) = 1[0,logN ](t) + e
−v2(N−1)(t−logN)1(logN,∞](t).
Let ǫ > 0. Then
P (u1X
′
2 > ǫ) = 1[0,logN ]
(
ǫ
u1
)
+ e−v2(N−1)(ǫ/u1−logN)1(logN,∞]
(
ǫ
u1
)
.
By our assumptions, u1 logN → 0 so for N large enough this becomes
P (u1X
′
2 > ǫ) = e
−v2(N−1)(ǫ/u1−logN).
Also by our assumptions, −v2(N − 1)(ǫ/u1 − logN) ∼ −v2Nǫ/u1 → −∞, so
P (u1X
′
2 > ǫ)→ 0.
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Proof of Proposition 14. Combining Lemmas 16 and 17 we get part 1 of Proposition 14.
As in model M2, u1X1 has the exponential distribution with parameter 1. To prove part 2 of
Proposition 14 we need to show that u1X2 →p 0. Let ǫ > 0. Then
P (u1X2 > ǫ) = P (X2 > ǫ/u1) = e
−ǫu2/u1 .
Since u2/u1 →∞ we have P (u1X > ǫ)→ 0.
Lastly we prove part 3 of Proposition 14. In model M3 both mutations occur on the stem
cell. In this case u1X1 and u2X2 are both exponentially distributed with parameter 1. Because
u1X2 = (u1/u2)u2X2 we have that u1X2 is exponentially distributed with parameter u2/u1. By
assumption, u2/u1 → 1/A so u1X2 converges in distribution to Z. The random variables X1 and
X2 are independent for each N so
u1τ(M3) = u1X1 + u1X2 →d X + Z.
6 Proof of the Theorem
We will couple the models H2, M1, M2 and M3 so that the Poisson processes used in models
M1, M2 and M3 are the appropriate subcollections of Poisson processes which are used in model
H2. Let T be the time that the stem cell becomes a type-1. Note, because the stem cell cannot
inherit a type-1 mutation and H2, M2 and M3 are coupled, that T will be the same for models
H2, M2 and M3.
Let X be exponentially distributed with parameter 1 and let Y be a random variable with
the Rayleigh distribution.
Lemma 18. Suppose v1v2 ≪ 1/N(logN)2. If u1 ≪ v1v2N logN then P (τ(M1) < T ) → 1. If
u1 ≫ v1v2N logN then P (τ(M3) < τ(M1))→ 1.
Proof. By part 1 of Proposition 7 (α ∧ 1)v1v2N(logN)τ(M1) →d X. Mutations to the stem
cell occur at rate u1 so u1T →d X. Because the mutations Poisson processes which mark the
mutations in model M1 are independent of the Poisson process that marks the mutations on the
stem cell, if u1 ≪ v1v2N logN then P (τ(M1) < T )→ 1 by Lemma 4.
On the other hand, suppose u1 ≫ v1v2N logN . We are assuming u1 ≤ u2 so we could decrease
P (τ(M3) < τ(M1)) by decreasing u2 to u1. Then the distribution of u1τ(M3) is the distribution
of the sum of two independent exponentially distributed random variables, P (u1τ(M3) ≤ t) ≥
1− e−t − te−t. By Lemma 4, P (τ(M3) < τ(M1))→ 1.
Lemma 19. Suppose 1/N(logN)2 ≪ v1v2 ≪ 1/N . If u1 ≪
√
v1v2N then P (τ(M1) < T ) → 1.
If u1 ≫
√
v1v2N then P (τ(M3) < τ(M1))→ 1.
Proof. Let u1 ≪
√
v1v2N . By part 2 of Proposition 7 we have
√
v1v2Nτ(M1) →d Y . The stem
cell is getting mutations at rate u1 so u1T → X. The Poisson processes that are marking the
mutations in modelM1 are independent of the Poisson process that marks mutations on the stem
cell, so the result follows by Lemma 4.
If u1 ≫ v1v2N logN then the proof follows by the same reasoning as used in Lemma 18 when
considering u1 ≫ v1v2N logN .
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Lemma 20. If v1v2 ≫ 1/N then P (τ(M1) < T )→ 1.
Proof. By part 3 of Lemma 7 we have
√
v1v2Nτ(M1)→d Y . The stem cell is getting mutations
at rate u1 so u1T → X. The Poisson processes that are marking the mutations in model M1 are
independent of the Poisson process that marks mutations on the stem cell, so the result follows
by Lemma 4 since u1 ≪ 1≪
√
v1v2N .
Lemma 21. If u2 ≪ 1/ logN and u2 ≪ Nv2 then P (τ(M2) < τ(M3))→ 1.
Proof. Because models M2 and M3 are coupled, the stem cell in each model will receive a type-1
mutation at the same time. After this the Poisson processes marking the mutations in models
M2 and M3 are independent. Let T2 be the time it takes for a type-2 mutation to occur in model
M2 after the stem cell has a type-1 mutation and let T3 be the time it takes for a type-2 mutation
to occur in model M3 after the stem cell has a type-1 mutation. Then P (τ(M2) < τ(M3)) =
P (T2 < T3).
Consider again the model M ′2 that was introduced in the proof of Lemma 17 which is the
same as model M2 except that the type-2 mutations can only occur on daughter cells logN time
after the stem cell has a type-1 mutation. We can couple models M2 and M
′
2 as we did before so
that the time of the stem cell mutation is the same in models M2 and M
′
2. Let T
′
2 be the time it
takes to acquire a type-2 mutation in model M ′2 after the stem cell has a type-1 mutation. Then
T ′2 ≥ T2 so it is enough to show that P (T ′2 < T3)→ 1.
If we wait logN time after the stem cell receives its type-2 mutation then all of the daughter
cells will be type-1. Then the (N − 1) daughter cells are getting type-2 mutations at rate v2.
Thus for any fixed N we have
P (T ′2 > t) = 1[0,logN ](t) + e
−v2(N−1)(t−logN)1(logN,∞](t).
Let ǫ > 0. Then
P (T ′2 < T3) = P (T
′
2 < T3|T3 < logN)P (T3 < logN) + P (T ′2 < T3|T3 ≥ logN)P (T3 ≥ logN).
Because u2 ≪ 1/ logN and u2T3 has the exponential distribution with parameter 1, P (T3 ≥
logN)→ 1. The memoryless property of the exponential distribution gives us that
P (T ′2 < T3|T3 ≥ logN) =
v2(N − 1)
v2(N − 1) + u2 → 1
which completes the proof.
Lemma 22. If u2 ≫ 1/ logN or u2 ≫ Nv2 then P (τ(M3) < τ(M2))→ 1.
Proof. Because models M2 and M3 are coupled, the stem cell in each model will receive a type-1
mutation at the same time. After this the Poisson processes marking the mutations in models
M2 and M3 are independent. Let T2 be the time it takes for a type-2 mutation to occur in model
M2 after the stem cell has a type-1 mutation and let T3 be the time it takes for a type-2 mutation
to occur in model M3 after the stem cell has a type-1 mutation. Then P (τ(M3) < τ(M2)) =
P (T3 < T2).
Suppose u2 ≫ 1/ logN . By Lemma 16 we know that ρ(M2)→p α ∧ 1. Therefore, if 0 < δ <
(α∧1) then P (ρ(M2) > (α∧1)− δ)→ 1. If ρ(M2) > (α∧1)− δ then the second mutation occurs
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on a generation higher than ((α ∧ 1) − δ)l. Since the stem cell is the only cell that gets type-1
mutations in model M2, this means that T2 ≥ ⌊((α∧1)− δ)l⌋ because it takes that much time for
the type-1 mutation to spread to the generation ((α∧ 1)− δ)l daughter cells. On the other hand,
in modelM3 the second mutation is occurring at rate u2 so that u2T3 is exponentially distributed
with parameter 1. Then P (T3 < K logN) = P (u2T3 < u2K logN)→ 1 for any positive number
K since u2 logN →∞. Therefore P (T3 < T2)→ 1.
Suppose u2 ≫ Nv2. The rate at which type-2 mutations occur in model M2 is always
bounded by (N − 1)v2. Suppose we consider a new model M ′′2 which is the same as M2 except
that once the stem cell has a type-1 mutation, all of the daughter cells also have a type-1 mutation
instantaneously. This can be coupled so that after the stem cell gets a type-1 mutation then any
type-2 mutation proposed by a Poisson process on a daughter cell is accepted in model M ′′2 .
Then if we let T ′′2 be the time it takes for a type-2 mutation to occur in model M
′′
2 after the stem
cell has a type-1 mutation, (N − 1)v2T ′′2 has the exponential distribution with parameter 1. By
Lemma 4, P (T3 < T
′′
2 )→ 1. Because T2 ≥ T ′′2 we have the desired result.
Proof of Proposition 1. From the coupling we have τ(H2) = τ(M1)∧ τ(M2)∧ τ(M3) because any
type-2 mutation which occurs in model H2 must occur in at least one of the models Mi for some
i, and if a mutation occurs in model Mi then it will also occur in model H2.
Suppose P (τ(M1) < T ) → 1. Before time T models models M2 and M3 are only acquiring
mutation on the stem cell. Therefore, models M2 and M3 only have type-0 cells before time T
and P (τ(M1) < τ(M2) ∧ τ(M3))→ 1.
• By Lemma 18 if v1v2 ≪ 1/N(logN)2 and u1 ≪ v1v2N logN then P (τ(M1) < T )→ 1 so by
part 1 of Proposition 7 and the coupling ofH2 withM1 we have (α∧1)v1v2N(logN)τ(H2)→d
X. The distribution of σ(H2) converges to a uniform distribution on ((1−α)+, 1] and ρ(H2)
converges in distribution to 1.
• By Lemma 19 if 1/N(logN)2 ≪ v1v2 ≪ 1/N and u1 ≪
√
v1v2N then P (τ(M1) < T ) → 1
so by part 2 of Proposition 7 and the coupling of H2 withM2 we have
√
v1v2Nτ(H2)→d Y .
Both σ(H2) and ρ(H2) converge in distribution to 1.
• By Lemma 20 if v1v2 ≫ 1/N then P (τ(M1) < T ) → 1 so by part 3 of Proposition 7 and
the coupling of H2 with M1 we have
√
Nv1v2τ(H2)→d Y . Both σ(H2) and ρ(H2) converge
in distribution to 1.
If either v1v2 ≪ 1/N(logN)2 and u1 ≫ v1v2N logN or 1/N(logN)2 ≪ v1v2 ≪ 1/N and
u1 ≫
√
v1v2N then P (τ(M3) < τ(M1)) → 1 by Lemmas 18 and 19 respectively. Therefore,
P (τ(M2) ∧ τ(M3) < τ(M1)) → 1 (meaning that the cancer causing type-1 mutation occurs on
the stem cell). Given these four conditions, we are left only to compare τ(M2) and τ(M3).
• By Lemma 21 if u2 ≪ 1/ logN and u2 ≪ Nv2 then P (τ(M2) < τ(M3)) → 1. Because
u1 ≤ u2 the hypotheses are true for u1 as well. Therefore, by the coupling of H2 with M2
and part 1 of Proposition 14 we have u1τ(H2)→d X. The distribution of ρ(H2) converges
to α ∧ 1.
• By Lemma 22 if u2 ≫ 1/ logN or u2 ≫ Nv2 then P (τ(M3) < τ(M2)) → 1. If u1 ≪ u2
then by the coupling of H2 with M3 and part 2 of Proposition 14 we have u1τ(H2)→d X.
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If u1 ∼ Au2 then by the coupling of H2 with M3 and part 3 of Proposition 14 we have
u1τ(H2)→d X+Z where Z is an exponentially distributed random variable with parameter
1/A that is independent of X.
By Lemma 6 the results hold for model H1 as well.
7 The Null Model
For this section we always have u1 = u2 = v1 = v2 = µ and we prove Proposition 2 for model
H2. Then Proposition 2 will hold for model H1 as well by Lemma 6. We begin this section
by pointing out that the conditions of part 5 of Theorem 1 always fail in the null model. The
two conditions in the first conjunction become µ ≪ 1/N logN . Of the two conditions in the
second conjunction, one becomes
√
N ≪ 1 which always fails. This reduces all of the conditions
in the first bullet point to µ ≪ 1/N logN . The conditions in the second bullet point become
µ ≫ 1/ logN or 1 ≫ N , so the conditions in part 5 can only hold if 1/ logN ≪ µ ≪ 1/N logN
which can never happen.
This shows that the probability that the first type-2 mutation occurs on the stem cell converges
to 0. For this reason, we will never consider model M3 in this section.
Proof of part 2 of Proposition 2. This time we first consider independent models M1 and M2
meaning we do not couple the Poisson processes that mark mutations on the cells within each
model. We construct a new model from models M1 and M2 which we will refer to as model M
−
1,2.
The Poisson processes of model M2 always mark the cells in model M
−
1,2. The Poisson processes
that mark the mutations in model M1 mark the daughter cells in model M
−
1,2 until the stem cell
has a type-1 mutation. After the stem cell has a type-1 mutation, the Poisson processes in model
M1 no longer mark any of the cells in model M
−
1,2. This way model M
−
1,2 behaves exactly like
model M2 after the stem cell has a type-1 mutation.
Model M−1,2 is the same as model H2 except that the stem cell cannot get type-2 mutations
and for logN time after the stem cell receives a mutation the type-2 mutations are suppressed on
daughter cells that have not inherited the type-1 mutation from the stem cell. Let T be the time
at which the stem cell has a mutation and let T2 = τ(M2) − T . By the same argument used in
Lemma 17 to show u1X
′
2 →p 0 we know µT2 →p 0. Also, from part 1 of Proposition 7 we know
P (µτ(M1) > t)→ e−At. Let ǫ > 0. Then
lim supP (µτ(H2) > t) ≤ lim supP (µτ(M−1,2) > t)
= lim sup (P ({µτ(M1) > t} ∩ {µT > t}) + P ({τ(M1) > T} ∩ {µT ≤ t} ∩ {µτ(M2) > t}))
≤ lim supP ({µτ(M1) > t})P ({µT > t}) + lim supP ({µT ≤ t} ∩ {µτ(M2) > t})
= e−(1+A)t + lim supP ({µT ≤ t} ∩ {µ(T + T2) > t})
≤ e−(1+A)t
+ lim sup(P ({µT ≤ t ≤ µ(T + ǫ)} ∩ {µT2 ≤ ǫ}) + P ({µT ≤ t ≤ µ(T + T2)} ∩ {µT2 > ǫ}))
≤ e−(1+A)t + lim supP (µT ∈ [t− ǫµ, t]) + lim supP (µT2 > ǫ)
= e−(1+A)t
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where the third line follows by the independence of τ(M1) and T and the last line follows because
µT is exponentially distributed, µ → 0 and µT2 →p 0. Hence we have lim supP (µτ(H2) > t) ≤
e−(1+A)t.
We define another model, M+1,2, which is the same as model M
−
1,2 except that we always count
the mutations from model M1. That is, we have models M1 and M2 and we are looking for
the first mutation that occurs on either of these models. We couple model M+1,2 with model
H2 so that before the stem cell has a mutation the Poisson processes marking the mutations in
modelsM1, M2 and H2 are the same and after the stem cell has a mutation the Poisson processes
marking the mutations in model M2 only mark those generations in model H2 which have not
yet inherited a type-1 mutation from the stem cell. If we wait logN time after the stem cell has
a mutation then the Poisson processes marking model M1 are not marking model H2. Then
lim inf P (µτ(H2) > t) ≥ lim inf P (µM+1,2 > t)
= lim inf P ({µτ(M1) > t} ∩ {µτ(M2) > t})
= lim inf P (µτ(M1) > t)P (µτ(M2) > t)
= e−(1+A)t
where the last equality follows by part 1 of Proposition 7. Combining this with the above result
we have limP (µτ(H2) < t) = 1− e−(1+A)t.
Note that lim supP (T = τ(M1)) = 0. Let ǫ > 0. By continuity of measure there exists δ > 0
such that lim supP (0 ≤ τ(M1)− T ≤ δ) < ǫ. Then
lim supP (τ(M1) < τ(M2))
= lim sup(P ({τ(M1) < τ(M2)} ∩ {τ(M1) < T}) + P ({τ(M1) < τ(M2)} ∩ {τ(M1) ≥ T}))
≤ lim supP (τ(M1) < T ) + lim supP (T ≤ τ(M1) ≤ T + T2)
≤ A
1 +A
+ lim supP (T ≤ τ(M1) ≤ T + δ|µT2 ≤ δ)
≤ A
1 +A
+ ǫ
where the fourth line follows because µT2 →p 0 and by Lemma 5. Because ǫ > 0 was arbitrary
we have lim supP (τ(M1) < τ(M2)) ≤ A/(1 +A). On the other hand,
lim inf P (τ(M1) < τ(M2)) ≥ lim inf P ({τ(M1) < T}) = A
1 +A
.
Let Z be a random variable such that Z = 1 if τ(M1) < τ(M2) and Z = 0 otherwise. If
τ(M1) < τ(M2) then σ(H2) = σ(M1) and ρ(H2) = ρ(M1). By Proposition 7 we know that σ(M1)
converges in distribution U and ρ(M1) converges in probability to 1. The event τ(M1) = τ(M2)
has probability 0. If τ(M1) > τ(M2) then σ(H2) = σ(M2) and ρ(H2) = ρ(M2). By definition of
model M2 we always have σ(M2) = 0 and by Proposition 14 ρ(M2) converges in probability to
α ∧ 1. Therefore,
σ(H2) = σ(M1)Z + σ(M2)(1 − Z)→d Uξ
and
ρ(H2) = ρ(M1)Z + ρ(M2)(1 − Z)→d ξ + (α ∧ 1)(1 − ξ).
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Let N be the set of Radon measures ν on a Polish space (Ψ,B) where B is the Borel σ-field
such that ν({x}) ∈ N ∪ {0,∞} for all x ∈ Ψ. For the next proof we will consider a point process
to be a random variable taking on elements of N . We consider ν({x}) to be the number of times
the point x has been marked. For a Poisson point process whose intensity measure has no atoms
ν({x}) is 0 or 1 for all x and {x ∈ Ψ : ν({x}) > 0} is discrete with probability 1.
Let Ψ = [0,∞) × [0, 1]. The Poisson point process of successful type-1 mutations in model
M1 induces a point process on Ψ where if a successful type-1 mutation occurs at time t on a cell
in generation i in model M1 then there is a point of Ψ at (t/l, i/l). We will call this point process
PM .
Lemma 23. The limiting distribution of PM is a Poisson point process P∞ which has intensity
measure ν ′ = A2(λ× λ[1/2,1]) where λ is Lebesgue measure and λ[1/2,1] is the measure defined by
λ[1/2,1](B) = λ(B ∩ [1/2, 1]) for any Lebesgue measurable set B.
Proof. We let CC(Ψ, [−1, 0]) be the set of continuous functions h : Ψ→ [−1, 0] such that the set
{ψ ∈ Ψ : h(ψ) 6= 0} is precompact. Recall that a point process X has an associated generating
functional F : CC(Ψ, [−1, 0]) → R defined by
F(h) = E[
∏
ψ∈Ψ
(h(ψ) + 1)ν(ψ)]
where ν is a Radon measure on Ψ as described above. Probability generating functionals uniquely
determine the distribution of point processes (see Theorem 14 of section 29.5 in [4]). Moreover,
a sequence of point processes converges in distribution to a point process if and only if the corre-
sponding sequence of generating functionals converges pointwise to a functional F that satisfies
the following: If hm is in the domain of F for each m,
⋃∞
m=1{ψ : hm(ψ) 6= 0} is relatively com-
pact, and hm(ψ) → 0 as m → ∞ for each ψ, then F(hm) → 1 as m → ∞. In this case F is the
probability generating functional of the limiting point process (see Theorem 20 of Section 29.7
in [4]).
Notice that for any N the points marked in Ψ will all have coordinates (x, y) where y takes
values in {1/ logN, 2/ logN, . . . , 1}. We know from the proof of Corollary 11 that the rate
at which mutations occur along generation i is bounded between 2i−1µ(1 − e−µ(2l−i+1−2)) and
2i−1µ(1 − e−µ(2l−i+1−1)). Therefore, if we look at the points that are marked in Ψ whose sec-
ond coordinate is fixed at i/ logN , the rate at which the marking will occur will be between
(logN)2i−1µ(1− e−µ(2l−i+1−2)) and (logN)2i−1µ(1− e−µ(2l−i+1−1)) where the logN appears be-
cause time is scaled by 1/ logN . This observation will allow us to work with time homogeneous
Poisson point processes.
Let F denote the generating functional associated with PM . Let F1 be the generating func-
tional associated with the Poisson process on Ψ which marks points at rate (logN)2i−1µ(1 −
e−µ(2
l−i+1−2)) on each generation and let F2 be the generating functional associated with the
Poisson process on Ψ which marks points at rate (logN)2i−1µ(1− e−µ(2l−i+1−1)) along each gen-
eration. Call the time homogeneous Poisson point processes P1 and P2 respectively. Because
the intensity measure of PM is always between the intensity measures of P1 and P2 we have the
bounds F1 ≤ F ≤ F2.
Let X be a Poisson process with intensity measure ν. It is known that the probability
generating functional associated with X is
P(h) = e−
∫
Ψ
hdν .
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To show a sequence of Poisson processes {Xn}∞n=0 with intensity measures {νn}∞n=0 converges in
distribution to a Poisson process X with intensity measure ν it is enough to show that {νn}∞n=0
converges weakly to ν. That is, for each h ∈ CC(Ψ, [−1, 0]) we need
∫
Ψ hdνn →
∫
Ψ hdν as n→∞.
Let ν1N be the intensity measure of P1 when there are N cells in the population and let ν
2
N be
the intensity measure of P2 when there are N cells in the population. The goal is to show ν
1
N
and ν2N both converge weakly to ν
′. Then the limiting distribution of PM will be P∞.
Let R = (a, b]× (c, d] ⊂ Ψ. Then
ν1N (R) = (a− b)(logN)
∑
i∈(lc,ld]
2iµ(1− e−µ(2l−i+1−2))→ A2(d− c ∨ 1
2
)+(b− a) = ν ′(R)
by Lemma 10 and the assumption that µ ∼ A/√N logN which implies µ2N logN ∼ A2/ logN .
Now let O be any open subset of Ψ. We can write O =
⋃∞
n=1Rn where each Rn is a half open
rectangle in the same form as R above and the sets {Rn}∞n=1 are pairwise disjoint. Then
lim inf
N→∞
ν1N (O) = lim inf
N→∞
∞∑
j=1
ν1N (Rj) ≥
∞∑
j=1
ν ′(Rj) = ν ′(O)
where the inequality follows by Fatou’s lemma. By the same reasoning lim inf ν2N (O) ≥ ν ′(O) for
any open subset O of Ψ. It follows by the Portmanteau Theorem that both ν1N and ν
2
N converge
weakly to ν ′ as N goes to infinity. Because of the bounds on the linear functionals we have that
the limiting distribution of PM is a Poisson process with intensity ν
′.
The notation used in Lemma 23 will also be used in this proof.
Proof of part 4 of Proposition 2. Notice that this is the boundary between two cases that are
determined by model M1. By Corollary 9 we know ρ(M1) →p 1 for all conditions that we are
considering. Therefore, ρ(H1)→p 1 in this case.
The strategy is to define functions g and h on the set of Radon measures that are continuous
everywhere except a set of measure 0. Then we will apply the Continuous Mapping Theorem
to get the desired convergence in distribution. Let D be the subset of N such that ν ∈ D if
there exists (x, y) ∈ Ψ and t ∈ R such that ν(x, y) > 0 and ν(x + t, y + t) > 0. For all t ≥ 0
define sets Tt = {(x, y) : 0 ≤ y ≤ 1/2 and 0 ≤ x ≤ y + t − 1} ⊂ Ψ. These sets correspond
the the triangles and quadrilaterals that were shown in the picture in the introduction. Let
V = {(x, y) ∈ Ψ : ν(x, y) > 0} and define t0 = inf{t : V ∩ Tt 6= ∅}. Define
g(ν) = lim
ǫ→0
sup
y
{y : (x, y) ∈ V ∩ Tt0+ǫ for some x}
and h(ν) = t0.
Given a Poisson point process P on Ψ whose intensity has no atoms, we can project the points
of P onto the line y = −x in R2 along perpendicular angles of π/4. With probability 1 no two
points of P will be mapped to the same point under the projection. That is, under the law of
P , D has probability 0. Moreover, with probability 1 there will be no limit points under the
projection. Therefore, under the intensity measure A2(λ[1/2,1] × λ), there exists a unique point
(x0, y0) ∈ V ∩Tt0 and an ǫ > 0 such that V ∩Tt0+ǫ = {(x0, y0)} with probability 1. By definition
g(P ) = y0. We claim that g and h are continuous at any Radon measure ν ∈ N\D.
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Let ν ∈ N\D and let {νn}∞n=1 be a sequence of Radon measures that converges weakly to ν.
Let ǫ > 0 and let (x0, y0) be the unique point of Tt0+ǫ such that ν(x0, y0) > 0. For each point
(x′, y′) ∈ Ψ and every natural number m define a function
f(x′,y′),m(x, y) =


−1 if |(x, y) − (x′, y′)| < ǫ/m
−(2−m|(x, y)− (x′, y′)|/ǫ) if ǫ/m ≤ |(x, y)− (x′, y′)| ≤ 2ǫ/m
0 otherwise
For m large enough we have
∫
Ψ f(x0,y0),m(x, y)dν = −1 so
∫
Ψ f(x0,y0),m(x, y)dνn → −1 as n →
∞ for large enough values of m. Because we can make m arbitrarily large, there must be a
sequence of points {(xn, yn)}∞n=1 such that νn(xn, yn) = −1 for all n and (xn, yn) → (x0, y0)
as n → ∞. Likewise, for any point (x′, y′) ∈ Tt0+ǫ there exists a large enough m such that∫
Ψ f(x′,y′),m(x, y)dν = 0 so
∫
Ψ f(x′,y′),m(x, y)dνn → 0 as n → ∞. This shows that for n large
enough the Radon measures νn will assign measure 0 to all points in a ball of radius ǫ/m about
(x′, y′). From this it is easy to conclude g(νn) → g(ν) and h(νn) → h(ν). Therefore, g and
h are both continuous on N\D. By Lemma 23 and the Continuous Mapping Theorem g(PM )
converges in distribution to g(P∞) and h(PM ) converges in distribution to h(P∞).
The next goal is to show that g(PM )−σ(M1)→p 0 and h(PM )−τ(M1)/ logN →p 0. Then we
will have that σ(M1)→d g(P∞) and τ(M1)/ logN →d h(P∞). To achieve this we will first show
that the probability that (x0, y0) corresponds to the cancer causing type-1 mutation converges in
probability to 1. Suppose (x0, y0) does not correspond to the cancer causing type-1 mutation and
let (x1, y1) denote the point in Ψ corresponding to the cancer causing type-1 mutation in M1.
Let ǫ > 0 and suppose that (x1, y1) /∈ Tt0+ǫ. The point (x0, y0) ∈ Tt0 corresponds to a successful
type-1 mutation in model M1, and by the way that model M1 marks points in Ψ there will be
a type-2 mutation in model M1 that corresponds to a point in Tt0 . The ray starting at (x1, y1)
with an angle of π/4 will represent all of the descendants of the cancer causing type-1 mutation.
The point on this line whose first coordinate is t0 will be (t0, y
′′) where y′′ ≤ 1 − ǫ. In this case
ρ(M1) = y
′′ ≤ 1− ǫ. Let E1 be the event that (x0, y0) is the point in Ψ that corresponds to the
cancer causing type-1 mutation and E2 be the event that two or more points occur in Tt0+ǫ. We
know that PM converges in distribution to P∞ by Lemma 23 so
lim supP (EC1 ) = lim sup(P (E
C
1 ∩ {(x1, y1) ∈ Tt0+ǫ}) + P (EC1 ∩ {(x1, y1) /∈ Tt0+ǫ}))
≤ lim supP (E2) + lim supP (ρ(M1) < 1− ǫ)
≤ A
2
2
ǫ
where the last line follows because ρ(M1) →p 0 and P (E2) ≤ P (V ∩ (Tt0+ǫ\Tt0) 6= ∅). Because
ǫ > 0 was chosen arbitrarily, we have limP (EC1 ) = 0.
The above has established that limP (E1) = 1. By definition of σ(M1) and g(PM ) it is clear
that
P (σ(M1)− g(PM ) = 0|E1) = 1
because σ(M1) = g(PM ) = y0. Conditional on the event E1 we also know that the cancer causing
type-1 mutation occurs at time (logN)x0. Let (x
′
0, y
′
0) be the point in Ψ that corresponds to
the type-2 mutation in M1, so that ρ(M1) = y
′
0. Let ν be the Radon measure of points in Ψ
induced by M1 and consider the fact that the descendants of the cancer causing type-1 mutation
will lie on a line starting at (x0, y0) with angle π/4. It is clear that h(ν) = t0 = x0 + 1− y0 and
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ρ(M1) = y0 + τ(M1)/ log(N) − x0. Thus, if h(ν) − τ(M1)/ logN > ǫ then 1 − ρ(M1) > ǫ, or
equivalently ρ(M1) < 1− ǫ. Therefore, because P (E1)→ 1,
P (h(PM )− τ(M1)/ logN > ǫ|E1) = P (ρ(M1) < 1− ǫ|E1)→ 0.
Again using the fact that P (E1)→ 1 we get the desired result.
Now we are left to show that g(P∞) and h(P∞) have the distributions that are stated in part
4 of Proposition 2. We have P (h(P∞) ≤ t) is the probability that a point of the Poisson process
with intensity A2(λ[1/2,1] × λ) has been marked in Tt. For t ≤ 1/2 this is 1 − e−A2t2/2 and for
t > 1/2 this is 1− e−A2t/2+A2/8. Therefore,
P (τ(M1)/ logN ≤ t)→ (1− e−A2t2/2)1[0,1/2](t) + (1− e−A
2t/2+A2/8)1(1/2,∞)(t).
To find the distribution of g(P∞) we will use the joint density function of g(P∞) and h(P∞).
From the above computation it is clear that the density of h(P∞) is
fh(t) = A
2te−A
2t2/21[0,1/2](t) +
A2
2
e−A
2t/2+A2/81(1/2,∞)(t).
Conditioned on the event that h(P∞) = t we know that g(P∞) will have uniform distribution. If
t ≤ 1/2 then g(P∞) is uniformly distributed on the interval [1 − t, 1]. If t > 1/2 then g(P∞) is
uniformly distributed on [1/2, 1]. This gives us the conditional density function
fg|h(s|t) =
{
1
t if 1− t ≤ s ≤ 1 and 0 ≤ t ≤ 12
2 if 12 ≤ s ≤ 1 and t > 12
.
Therefore, the joint density function of g(P∞) and h(P∞) is
f(s, t) = A2e−A
2t2/21[0,1/2](t)1[1−t,1/2](s) +A2e−A
2t/2+A2/81(1/2,∞)(t)1[1/2,1](s).
Integrating over t we find that the density of g(P∞) is
fg(s) =
(∫ 1/2
1−s
A2e−A
2t2/2dt+ 2e−A
2/8
)
1[1/2,1](s).
This gives the desired limiting distribution for model M1. By the same arguments as used
above, the results will hold for model H1 as well.
Proof of part 6 of Proposition 2. First we change model M1 so that only generation l − 1 will
get type-1 mutations and generation l will get type-2 mutations. Also, assume that only one of
the daughters will keep a mutation when the cells split so that if a type-1 cell splits it has a
type-0 daughter and a type-1 daughter. The rate at which the type-1 mutations occur will be
µN/4 since there are N/4 cells in generation l − 1. Note that µN/4 ∼ A√N/4. The probability
that a type-1 mutation will have a type-2 descendant is 1 − eµt ∼ µt ∼ At/√N . Therefore,
the type-2 mutations occur according to a Poisson process whose intensity measure ν satisfies
ν([0, t]) ≥ (A√N/4)(At/√N) = A2t/4. We have may have to wait up to two time units for the
type-2 mutation to occur after the successful type-1 appears. For the sake of a lower bound we will
always assume it takes 2 time units after a successful type-1 mutation until the type-2 mutation.
By coupling this model with model H2, this gets us lim inf P (τ(M1) ≤ t) ≥ 1− e−2−A2t/4.
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For the upper bound we change model M1 so that the type-1 cells never undergo apoptosis.
There are N cells getting type-1 mutations so the type-1 mutations occur at rate µN ∼ A√N. If
we wait t time until after a type-1 mutation has occurred the cell will have at most 2t descendants.
If the type-1 mutation had occurred at time 0 and all of the descendants had existed since
the type-1 mutation occurred then the probability that one of the cells had acquired a type-2
mutation would be t2⌊t⌋µ ≤ t2tµ ∼ t2tA/√N . Because the type-1 mutation may occur after
time 0 and there have not been 2t descendants with the type-1 mutation since the mutation
occurred this is an upper bound on the probability that a type-2 mutation has occurred by
time t. Therefore, the type-2 mutations occur according to a Poisson process with intensity
ν([0, t]) ≤ (A√N)(t2tA/√N) = t2tA2. Then lim supP (τ(M1) ≤ t) ≤ 1 − e−A22tt. This shows
part 6 of Proposition 2 with c = 1− e−2−A2t/4 and C = 1− e−A22tt.
By Corollary 9 we know ρ(M1)→ 1. By the definitions of σ(M1) and ρ(M1) for any ǫ > 0 if
ρ(M1)− σ(M1) > ǫ then τ(M1) > ǫ logN . Therefore,
P (ρ(M1)− σ(M1) > ǫ) ≤ P (τ(M1) > ǫ logN) ≤ e−A22δ logN (δ logN) → 0.
Let ǫ > 0 and δ > 0 and choose N large enough so that P (1 − ρ(M1) > ǫ/2) < δ/2 and
P (ρ(M1)− σ(M2) > ǫ/2) < δ/2. Then
P (1− σ(M1) > ǫ) = P (1− ρ(M1) + ρ(M1)− σ(M1) > ǫ)
≤ P (1− ρ(M1) > ǫ/2) + P (ρ(M1)− σ(M1) > ǫ/2)
< δ.
Therefore, σ(M1)→p 1.
Using the same techniques as in the previous sections, we get the same results for H1.
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